Autotaxin inhibitors: A perspective on initial medicinal chemistry efforts

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 12, 2010, Pages 1619-1625

  Parrill, Abby L ^a   Baker, Daniel L ^a  

^a University of Memphis   (United States)

Author keywords

autotaxin; cancer; lysophosphatidic acid; lysophospholipase D; NPP2

Indexed keywords

AUTOTAXIN; AUTOTAXIN INHIBITOR; BITHIONOL; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; NAPHTHYRIDINE DERIVATIVE; PF 8380; PHOSPHONIC ACID DERIVATIVE; PIPEMIDIC ACID; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NONHUMAN; PATENT; PROTEIN FUNCTION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LIPID METABOLISM; MULTIENZYME COMPLEXES; NEOPLASMS; PHOSPHODIESTERASE I; PYROPHOSPHATASES;

EID: 78649239509     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.533658     Document Type: Review

References (49)

1. Bollen M, Gijsbers R, Ceulemans H, et al. Nucleotide pyrophosphatases/ phosphodiesterases on the move. Crit Rev Biochem Mol Biol 2000;35(6):393-432
2. Stracke ML, Krutzsch HC, Unsworth EJ, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992;267(4):2524-9
3. Murata J, Lee HY, Clair T, et al. cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J Biol Chem 1994;269(48):30479-84
4. Tokumura A, Majima E, Kariya Y, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002;277(42):39436-42
5. Umezu-Goto M, Kishi Y, Taira A, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002;158(2):227-33
6. Tokumura A, Yamano S, Aono T, et al. Lysophosphatidic acids produced by lysophospholipase D in mammalian serum and body fluid. In: Goetzl EJ, Lynch KR, editors, Lysophospholipids and eicosanoids in biology and pathophysiology. New York Academy of Sciences, New York; 2000. p. 347-50
7. Tanaka M, Okudaira S, Kishi Y, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 2006;281(35):25822-30
8. van Meeteren LA, Ruurs P, Stortelers C, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006;26(13):5015-22
9. Koike S, Keino-Masu K, Masu M. Deficiency of autotaxin/lysophospholipase D results in head cavity formation in mouse embryos through the LPA receptor-Rho-ROCK pathway. Biochem Biophys Res Commun 2010;400(1):66-71
10. Ferry G, Giganti A, Coge F, et al. Functional invalidation of the autotoxin gene by a single amino acid mutation in mouse is lethal. FEBS Lett 2007;581(18):3572-8
11. Ferry G, Tellier E, Try A, et al. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 2003;278(20):18162-9
12. Bourgoin SG, Zhao C. Autotaxin and lysophospholipids in rheumatoid arthritis. Curr Opin Investig Drugs 2010;11(5):515-26
13. Inoue M, Ma L, Aoki J, et al. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol Pain 2008;4:6
14. Inoue M, Xie W, Matsushita Y, et al. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neuroscience 2008;152(2):296-8
15. Okudaira S, Yukiura H, Aoki J. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 2010;92(6):698-706
16. Samadi N, Bekele R, Capatos D, et al. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie. DOI: 10.1016/j.biochi.2010.08.002
17. Boucher J, Quilliot D, Praderes JP, et al. Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia 2005;48(3):569-77
18. Parrill AL, Baker DL. Autotaxin inhibition: challenges and progress toward novel anti-cancer agents. Anticancer Agents Med Chem 2008;8(8):917-23
19. Federico L, Pamuklar Z, Smyth SS, et al. Therapeutic potential of autotaxin/lysophospholipase d inhibitors. Curr Drug Targets 2008;9(8):698-708
20. Harper K, Arsenault D, Boulay-Jean S, et al. Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation. Cancer Res 2010;70(11):4634-43
21. Vidot S, Witham J, Agarwal R, et al. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal 2010;22(6):926-35
22. David M, Wannecq E, Descotes F, et al. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One 2010;5(3):e9741
23. Clair T, Koh E, Ptaszynska M, et al. L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin. Lipids Health Dis 2005;4(1):5
24. Tokumura A, Miyake M, Yoshimoto O, et al. Metal-ion stimulation and inhibition of lysophospholipase D which generates bioactive lysophosphatidic acid in rat plasma. Lipids 1998;33(10):1009-15
25. Lee HY, Clair T, Mulvaney PT, et al. Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin. J Biol Chem 1996;271(40):24408-12
26. Van Meeteren LA, Ruurs P, Christodoulou E, et al. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem 2005;280(22):21155-61
27. Ferry G, Moulharat N, Pradere JP, et al. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther 2008;327(3):809-19
28. Altman MK, Gopal V, Jia W, et al. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer 2010;9:140
29. Albers HM, van Meeteren LA, Egan DA, et al. Discovery and optimization of boronic acid based inhibitors of autotaxin. J Med Chem 2010;53(13):4958-67
30. Gierse JK, Thorarensen A, Beltey K, et al. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J Pharmacol Exp Ther 2010;334(1):310-17
31. Schiemann K, Schultz M, Staehle W, et al. Preparation of 2,5-diamino-substituted pyrido[4,3-d]pyrimidines as autotaxin inhibitors useful in treating cancer. Merck Patent GmbH, Germany. Application: WO2010063352, 2010. p. 177
32. Staehle W, Kober I, Schiemann K, et al. Preparation of benzo[b][1,6] naphthyridines as inhibitors of autotaxin for the treatment of tumors. Merck Patent GmbH, Germany. Application: WO, 2010. p. 142
33. Saunders LP, Ouellette A, Bandle R, et al. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Ther 2008;7(10):3352-62
34. Braddock D. Small molecule inhibitors of autotaxin, and methods of use for the treatment of cancer. Yale University, USA. Application: WO2009151644, 2009. p. 82
35. Schiemann K, Schultz M, Blaukat A, et al. Preparation of carbamoylthiazoles as anticancer agents. Merck Patent GmbH, Germany. Application: WO2009046842, 2009. p. 102
36. Hoeglund AB, Bostic HE, Howard AL, et al. Optimization of a pipemidic acid autotaxin inhibitor. J Med Chem 2010;53(3):1056-66
37. Hoeglund AB, Howard AL, Wanjala IW, et al. Characterization of non-lipid autotaxin inhibitors. Bioorg Med Chem 2010;18(2):769-76
38. North EJ, Howard AL, Wanjala IW, et al. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors. J Med Chem 2010;53(8):3095-105
39. Jansen S, Stefan C, Creemers JW, et al. Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D. J Cell Sci 2005;118(Pt 14):3081-9
40. Miller DD, Tigyi GJ, Gududuru V, et al. Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors. USA. Application: US2006270634, 2006. p. 21
41. Prestwich G, Tigyi G, Jiang G, et al. Antitumor alpha-Chloro AND alpha-Bromo phosphonate analogs of lysophosphatidic acid. University of Utah Research Foundation, USA; University of Tennessee Research Foundation. Application: WO2008157361, 2008. p. 65
42. Parrill-Baker AL, Baker DL, Montedonico LE. Preparation of fluoromethylphenyl phosphodiesters as mechanism-based inactivators of autotaxin. USA. Application: WO2010040080, 2010. p. 38
43. Takakusa H, Kikuchi K, Urano Y, et al. Design and synthesis of an enzyme-cleavable sensor molecule for phosphodiesterase activity based on fluorescence resonance energy transfer. J Am Chem Soc 2002;124(8):1653-7
44. Ferguson CG, Bigman CS, Richardson RD, et al. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org Lett 2006;8(10):2023-6
45. Moulharat N, Fould B, Giganti A, et al. Molecular pharmacology of adipocyte-secreted autotaxin. Chem Biol Interact 2008;172(2):115-24
46. Zhang H, Xu X, Gajewiak J, et al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res 2009;69(13):5441-9
47. Albers HM, Dong A, van Meeteren LA, et al. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci USA 2010;107(16):7257-62
48. Jansen S, Andries M, Vekemans K, et al. Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett 2009;284(2):216-21
49. Ueda H. Therapeutic or prophylactic agent for generalized pain syndrome. Nagasaki University, Japan; Argenes, Inc. Application: WO2010016590, 2010. p. 48